The Effect of Transcatheter VSD Closure on Children’s Appetite, Hormones and Growth

Related Clinical Trial
Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® mVSD Cases A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects The Effect of Transcatheter VSD Closure on Children’s Appetite, Hormones and Growth The Effect of Transcatheter Ventricular Septal Defect Closure on Heart Rate Variability Parameters Improving Care for Children With Congenital Heart Disease. Lifetech MFO Post-Market Clinical Follow-Up Study Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics Optical Tissue Identification for Myocardial Architecture Measures to Lower the Stress Response in Pediatric Cardiac Surgery Cardiac Function After Transcatheter VSD Closure The Effect of Remote Ischemic Preconditioning on the Ischemic Reperfusion Injury in Infants With Ventricular Septal Defect and Pulmonary Hypertension A Trial to Evaluate the Safety and Efficacy of a Fully Degradable Ventricular Septal Defect (VSD) Closure Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder – Post Approval Study The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects. Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol Optimal Timing for Repair of Left to Right Shunt Lesions Use of Ketamine Prior to Cardiopulmonary Bypass in Children Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow Transcatheter Closure Versus Surgery of Perimembranous Ventricular Septal Defects Cardiopulmonary Function in Adults Born With a Ventricular Septal Defect Longterm Outcome After Ventricular Septal Defect Closure Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER Hybrid Closure of Congenital Heart Disease

Brief Title

The Effect of Transcatheter VSD Closure on Children's Appetite, Hormones and Growth

Official Title

Nutritional, Hormonal and Anthropometric Evaluation of Children After Transcatheter VSD Closure

Brief Summary

      In this study; Changes in appetite, hormones and growth of ventricular septal defect patients
      treated with non-surgical method were evaluated.

Detailed Description

      The study included 20 patients whose ventricular septal defect closed percutaneously and 26
      children as control group. The symptoms, anthropometric measurements and laboratory tests of
      patient group were recorded at initial, 1st month and 6th months after closure.

      Anthropometric measurements; weight for age (WFA), height for age (HFA), body mass index
      (BMI) and their z scores, triceps skinfold thickness (TSF) and mid-upper arm circumference
      (MUAC) were recorded on admission. Patients with weight for height z score less than -2 were
      defined as malnutrition.

      Questions about the symptoms like appetite, weight gain, frequency of illness, rate of
      breathing, fatigue were asked to all parents at initial. These questionnaires15 and visual
      analogue scale (for appetite) were repeated at 1st and 6th month visits.

      During the initial evaluation, approximately 6 ml of venous blood samples were taken between
      9:00-10:00 am after an average of 10 hours fasting. On the same day, IGFBP-3, Ghrelin and
      leptin,fasting blood glucose, insulin, IGF-1, IGFBP-3, aspartate aminotransferase (AST) and
      alanine aminotransferase (ALT), total protein, and albumin were measured.

      Anthropometric measurements and laboratory tests were repeated at 1st and 6th month visits.

Study Type


Primary Outcome

Weight Z score


Ventricular Septal Defect

Study Arms / Comparison Groups

Description:  Patients whose ventricular septal defect closed percutaneously.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

July 16, 2018

Completion Date

January 1, 2020

Primary Completion Date

June 1, 2019

Eligibility Criteria

        Inclusion Criteria:

        Pediatric patients who underwent transcatheter VSD closure

        Exclusion Criteria:

          -  Chromosomal abnormalities

          -  Additional systemic disease

          -  Systemic infections




3 Months - 18 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Onur Tasci, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Kayseri City Hospital

Study Sponsor

Onur Tasci, Principal Investigator, TC Erciyes University

Verification Date

January 2022